NasdaqGS - Delayed Quote USD
Relmada Therapeutics, Inc. (RLMD)
At close: October 22 at 4:00 PM EDT
Insider Purchases Last 6 Months
Shares | Transactions | |
---|---|---|
Purchases | 0 | 0 |
Sales | -- | 0 |
Net Shares Purchased (Sold) | 0 | 0 |
Total Insider Shares Held | 2.43M | -- |
% Net Shares Purchased (Sold) | -- | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
Shares | |
---|---|
Net Shares Purchased (Sold) | -- |
% Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
Insider | Transaction | Type | Value | Date |
---|---|---|---|---|
TRAVERSA SERGIO Chief Executive Officer | Purchase at price 2.71 - 2.99 per share. | Direct | 395,115 | Sep 11, 2024 |
SHENOUDA MAGED R Chief Financial Officer | Purchase at price 2.55 - 2.95 per share. | Direct | 149,701 | Sep 11, 2024 |
CASAMENTO CHARLES J Director | Purchase at price 2.56 per share. | Direct | 33,280 | Sep 9, 2024 |
KELLY PAUL EDWARD Director | Purchase at price 2.59 per share. | Direct | 64,750 | Sep 9, 2024 |
TRAVERSA SERGIO Chief Executive Officer | Purchase at price 3.71 - 4.00 per share. | Direct | 386,738 | Jan 31, 2024 |
SHENOUDA MAGED R Chief Financial Officer | Purchase at price 3.65 - 4.06 per share. | Direct | 125,717 | Jan 31, 2024 |
ENCE CHARLES Officer | Purchase at price 3.65 - 4.05 per share. | Direct | 150,920 | Jan 31, 2024 |
O'GORMAN CEDRIC Officer | Purchase at price 3.18 per share. | Direct | 31,800 | May 23, 2023 |
TRAVERSA SERGIO Chief Executive Officer | Purchase at price 2.10 per share. | Direct | 115,804 | Dec 8, 2022 |
Related Tickers
YMAB Y-mAbs Therapeutics, Inc.
14.85
+1.99%
APLT Applied Therapeutics, Inc.
8.72
-3.00%
TCRX TScan Therapeutics, Inc.
5.24
-0.57%
ALEC Alector, Inc.
4.7000
+1.95%
INZY Inozyme Pharma, Inc.
5.11
-3.22%
SYRE Spyre Therapeutics, Inc.
34.15
+5.30%
MRUS Merus N.V.
53.19
+3.08%
NAMS NewAmsterdam Pharma Company N.V.
18.92
-0.53%
ALRN Aileron Therapeutics, Inc.
3.6700
+2.80%
VTYX Ventyx Biosciences, Inc.
2.2500
-5.86%